Urofollitropin - Ferring

Drug Profile

Urofollitropin - Ferring

Alternative Names: Bravelle; Ferring hFSH; HP FSH; Natural human follicle-stimulating hormone; Naturally derived follicle stimulating hormone

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Follicle stimulating hormones; Infertility therapies; Menotropins; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 01 Aug 2015 Ferring Pharmaceuticals completes a phase III trial for Female infertility in China (NCT01923194)
  • 01 Apr 2015 Ferring Pharmaceuticals completes a phase III trial in Female infertility in China (NCT01922193)
  • 19 Feb 2014 Ferring Pharmaceuticals receives FDA labelling approval for mixed protocol IVF treatment combining urofollitropin and menotropin in a single syringe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top